Skip to main content
. 2025 Sep 19;12(6):1057–1081. doi: 10.1007/s40744-025-00794-2

Table 2.

Annualized outcomes at 12 months for Veterans Affairs patients with gout

Outcomesa Controlled
(n = 193,596)
Uncontrolled
(n = 138,068)
p value
Length of follow-up, %
 Patients with 12 months or more of follow-up 187,626 (97%) 134,558 (97%)  < 0.001
Healthcare utilization, %
 Any clinic visit 193,594 (100%) 138,068 (100%) 0.771
 Primary care visit 191,175 (99%) 136,898 (99%)  < 0.001
 Podiatry visit 58,933 (30%) 52,071 (38%)  < 0.001
 Rheumatology visit 17,578 (9%) 33,730 (24%)  < 0.001
 Nephrology (with dialysis) visit 23,988 (12%) 33,374 (24%)  < 0.001
Symptoms, %
 Gout flare 8338 (4%) 19,888 (14%)  < 0.001
sUA labs and levels, %
 sUA lab drawn during follow-up 131,323 (68%) 128,841 (93%)  < 0.001
 sUA level > 6 during follow-up 70,847 (54%) 119,028 (92%)  < 0.001
 sUA level > 8 during follow-up 3999 (3%) 94,698 (74%)  < 0.001
Complications and outcomes, %
 Amputation 1605 (< 1%) 1653 (1%)  < 0.001
 Emergency room visit 74,383 (38%) 75,413 (55%)  < 0.001
 Urgent care visit 14,705 (8%) 13,699 (10%)  < 0.001
 Hospital visit 70,769 (37%) 64,362 (47%)  < 0.001
 Death 18,770 (10%) 13,571 (10%) 0.201

asUA serum uric acid